Patient stratification is one drug development area that stands to benefit from a biomarker solution developed for the National Cancer Institute. OncologyMAP aims also to help with drug re-tasking and indication-expansion efforts.
The details of 101 cancer-related proteins make up the core of the biomarker tool, developed by Rules-Based Medicine in Austin, TX. Drug efficacy and safety tests done via the panel are validated to clinical lab standards. So biomarker pattern discoveries made in basic research should be reproducible in clinical trials, the company says.
OncologyMAP is based on RBM's multi-analyte profiling platform, which characterizes blood-based biomarkers representing dozens of biological pathways.
- see the RBM release